Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part D Rebate Pass-Throughs To Beneficiaries Is 'On The Table'

Executive Summary

Lilly CEO David Ricks reflects on the state of play on drug pricing issues on Capitol Hill and in the Administration and the challenges he sees ahead.

You may also be interested in...



Medicare May Require Part D Plans To Provide Point-of-Sale Rebates

CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.

CMS Proposal On Part D May Address Drug Costs, But Will It Target Prices?

Upcoming proposed rule on Medicare Part D and Medicare Advantage prompts speculation about whether CMS is planning new measures to control spending on prescription drugs.

Medicare Part D Premiums Dip As Rebates Grow Faster Than Drug Costs To Plans

News that premiums will be lower in 2018 aligns with President Trump's concern with lowering drug costs, Administration officials announce.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel